Evidence map›Paper›PMID 41930303›Full record

ArticleESMO real world data and digital oncology2026

Histotype-specific incidence and survival of urothelial carcinoma-an analysis of the German North Rhine-Westphalia Cancer Registry.

C Darr, L Möller, A Szentkiralyi, K Claassen, N Schürger, H Reis, T Hilser, A Stang, B A Hadaschik, H Kajüter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

C DarrDepartment of Urology, University Hospital Essen, Essen, Germany.
L MöllerCancer Registry of North Rhine-Westphalia, Bochum, Germany.
A SzentkiralyiCancer Registry of North Rhine-Westphalia, Bochum, Germany.
K ClaassenCancer Registry of North Rhine-Westphalia, Bochum, Germany.
N SchürgerDepartment of Urology, University Hospital Essen, Essen, Germany.
H ReisDr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
T HilserDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
A StangCancer Registry of North Rhine-Westphalia, Bochum, Germany.
B A HadaschikDepartment of Urology, University Hospital Essen, Essen, Germany.
H KajüterCancer Registry of North Rhine-Westphalia, Bochum, Germany.
V GrünwaldDepartment of Urology, University Hospital Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The aim of this study was to evaluate the incidence and survival of urothelial carcinoma (UC) and non-urothelial tumor types. The primary objective was to define the incidence and survival of pure UC and non-UC tumor types. Materials and methods: Malignant invasive urinary cancers of the urothelial tract diagnosed between 2008 and 2022 were identified via the North Rhine-Westphalia Cancer Registry and classified according to the 2016 World Health Organization (WHO) classification (fourth edition). Evaluation focused on pure tumor types: UC, papillary invasive UC (PIUC), squamous-cell carcinoma (SCC), adenocarcinoma (ADC), rarer tumor types and mixed histologies grouped under other specific tumor types (OSTT), and unspecified tumor types (UTT). The primary outcomes were age-standardized incidence rate with estimated annual percentage changes, and relative survival. Results: UC and PIUC were the most common histology types, accounting for 57.9% and 26.2% ( Conclusion: Relative survival was most favorable for PIUC, UC, and ADC. In contrast, SSC and OSTT exhibited poorer survival outcomes, highlighting a pressing medical need for enhanced treatment options for these subgroups.

Indexed as

Germanyrare cancerregistriesrelative survivalurothelial carcinomavariant histology

Identifiers

PMID41930303
PMCPMC13040895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.